Australia's most trusted
source of pharma news
Monday, 02 February 2026
Posted 28 January 2026 AM
Infensa Biosciences’ cardioprotective drug candidate IB409 has entered human clinical trials, with the company’s co-founder, Bob Graham, describing the milestone as “a moment of truth”.
“Administering a brand-new therapy into humans for the first time is always a moment of truth,” Graham said.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.